Market Analysis and Insights: Global Fibromyalgia Therapeutics Drugs Market
Due to the COVID-19 pandemic, the global Fibromyalgia Therapeutics Drugs market size is estimated to be worth US$ 2918.9 million in 2022 and is forecast to a readjusted size of US$ 3239.1 million by 2028 with a CAGR of 1.8% during the review period. Fully considering the economic change by this health crisis, Cymbalta (Duloxetine) accounting for % of the Fibromyalgia Therapeutics Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Fibromyalgia Therapeutics Drugs market size is valued at US$ million in 2021, while the US and Europe Fibromyalgia Therapeutics Drugs are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Fibromyalgia Therapeutics Drugs landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Fibromyalgia Therapeutics Drugs include Pfizer, Eli Lilly, Actavis, Merck Sharp and Dohme, Daiichi Sankyo, Innovative Med Concepts, Meda, Meiji Seika and Switch Biotech, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Fibromyalgia Therapeutics Drugs Scope and Segment
Fibromyalgia Therapeutics Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Fibromyalgia Therapeutics Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Cymbalta (Duloxetine)
Savella (Milnacipran)
Lyrica (Pregabalin)
Pancuronium
Others
Segment by Application
Hospital
Clinic
Others
By Company
Pfizer
Eli Lilly
Actavis
Merck Sharp and Dohme
Daiichi Sankyo
Innovative Med Concepts
Meda
Meiji Seika
Switch Biotech
Theravance
Zynerba Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. (TNXP)
Daiichi Sankyo
Forest Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Pierre Fabre Mdicament
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE